| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
In colorectal cancer, HOPX hypermethylation is closely associated with poorly differentiated histology. As EphA2 is also known to be characteristics to poorly differentiate histology in CRC, and EphA2 was identified as a potential downstream target of HOPX in our previous studies, we are focusing on EphA2 as a therapeutic target in CRC. EphA2 expression is found in 15 out of poorly differentiated CRC, 12 from moderately differentiated CRC, and only 6 cases of 20 highly differentiated CRC (p=0.0083). We then examined 21 poorly differentiated CRC in detail, and EphA2 expression was recognized in about half cases with HOPX hypermethylation (n=11), while EphA2 expression was defective in 2 cases with HOPX hypomethylation. These finding suggested that HOPX may be causative molecule to overexpress EphA2 in primary CRC. In conclusion, EphA2 might be the optimal therapeutic target in primary CRC.
|
